Tuesday, November 19, 2024

What Makes SpotHero Clone the Perfect Solution for Parking Challenges?

Due to the increasing concentration of people...

Unlock Business Growth with Full Cycle Software Development Services

In today's fast-paced digital world, businesses in...

Carl Icahn supports new Illumina CEO Thaysen after proxy fight

HealthCarl Icahn supports new Illumina CEO Thaysen after proxy fight

[ad_1]

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.

David A. Grogan | CNBC

Carl Icahn on Thursday expressed his support for Illumina‘s new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire activist investor. 

“I think he will do an excellent job and he has my full support,” Icahn said in a post on X, noting that he spoke with Thaysen. 

Icahn, who continues to own a small stake in Illumina, launched a proxy battle over the company’s decision to close its $7.1 billion acquisition of cancer test developer Grail in 2021 without approval from antitrust regulators in U.S. and European Union. 

Icahn was a staunch critic of Illumina’s former CEO Francis deSouza, who ultimately resigned after the proxy battle in May despite securing enough votes to stay. 

“I’d find it comical, if it wasn’t so reprehensible that ILMN’s share price is down 63% due to CEO Francis deSouza making such an absurd and questionable purchase,” Icahn said in a statement to CNBC in March.

Jacob Thaysen

Source: Illumina

Shares of Illumina are now down nearly 70% since closing the Grail deal in August 2021. The company’s market value has fallen to roughly $25 billion from around $75 billion in August 2021.

Investors will be watching to see how Thaysen approaches the Grail business, and whether he can rebuild the market value the company lost.

Thaysen will step in as Illumina’s CEO on Sept. 25 after nearly a decade at medical devices firm Agilent Technologies, where he ran its largest analytical-lab unit, and doubled the division’s operating profit.

See also  These health-care companies see opportunity ahead from Alzheimer's drug approval



[ad_2]

Source link

Check out our other content

Check out other tags:

Most Popular Articles